FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation

Dec 2

Written By Team Rxtrospect

GET A DEMO

Team Rxtrospect

FDA approves atezolizumab for alveolar soft part sarcoma

RxTROSPECT, Inc 2025 — All rights reserved. “RxTROSPECT” refers to RxTROSPECT, Inc.. RxTROSPECT, Inc. is an intelligence company offering a range of data and analytics products through its partnerships with Tableau, LLC (a subsidiary of Salesforce, Inc), and Mango Technologies, Inc. dba ClickUp.

Testimonials are specific to an individual Customer’s experience and may not be representative of all Customers. Unless otherwise indicated, Customers offering a Testimonial do not receive compensation and their statement does not present a conflict of interest.

RxTROSPECT is not affiliated with, sponsored, or endorsed by the companies listed, described, or featured on its site. Company logos or trademarks used do not imply endorsement and are the property of their respective owners.

This is a representative list of customers that work with RxTROSPECT as of January 1st, 2025. It is not known whether they approve or disapprove of our products.

FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation

FDA approves atezolizumab for alveolar soft part sarcoma

FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer

solutions

ABOUT US

RESOURCES